The ACH showed potential as an anti-obesity and anti-diabetic agent by inhibiting pancreatic lipase by up to 43.4% at 0.063 mg/mL, α-amylase by up to 70% at 7.0 mg/mL and α-glucosidase by up to 67.6% at 100 mg/mL, respectively. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.